CRI, Oncovir sign fresh investment agreement to produce immunological stimulant Cancer Study Institute, Inc. , a U.S. Nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancers immunotherapies, announced today that its Cancer Vaccine Acceleration Fund , a joint initiative with the Ludwig Institute for Malignancy Research , has completed a new investment agreement with Oncovir, Inc., a biotechnology company based in Washington, D.C., to enable the creation of the immunological stimulant Hiltonol – . CVAF support is a crucial factor enabling the produce of enough high-quality Hiltonol – for scientific testing not only in cancer vaccines, also for many other diseases that it holds promise, says Andres M.A bad debt charge for these receivables was recorded in the next quarter of 2009. The Company has subsequently determined a portion of this charge related to prior periods. The effect of correcting this error, and the associated tax effect, has been documented in the relevant restated periods. The web result of these adjustments was a decrease in revenues of $5.7 million, $13.5 million, $10.3 million and $2. Net reduction elevated by $1.9 million and $10.june 30 1 million in the year ended, 2008 and the half a year ended December 27, 2008, respectively, and reduced by $7.8 million in the year ended December 26, 2009..